CERo Therapeutics Holdings entered into a Stock Purchase Agreement to sell all shares of its operating subsidiary, CERo Therapeutics, to SRX Global. Consideration includes $1.0 million of SRX common stock (priced by the lower of prior-day close or 20-day VWAP), forgiveness of obligations under a senior secured note (originally up to $11.67 million; $8.25 million outstanding) plus accrued amounts, and SRX’s assumption of about $1.56 million of specified liabilities. The agreement includes a 30-day go-shop and customary closing conditions, including preferred stockholder consents. CERo expects the transaction to reduce debt and reposition the holding company.
Agreement details:
- Agreement type: Stock Purchase Agreement for sale of all…